MedTrace Logo

A Study of NPC-22 in Healthy Adult Males

NCT04203862 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-08-06

No results posted yet for this study

Summary

The purpose of this trial is to examine the safety and pharmacokinetics of NPC-22 administered in a single ascending dose in healthy adult males.

Conditions

  • Healthy Adult Subjects

Interventions

DRUG

NPC-22

Single administration of low dose NPC-22

DRUG

NPC-22

Single administration of low/middle dose NPC-22

DRUG

NPC-22

Single administration of middle dose NPC-22

DRUG

NPC-22

Single administration of middle/high dose NPC-22

DRUG

NPC-22

Single administration of high dose NPC-22

DRUG

NPC-22 Placebo

Single administration of NPC-22 Placebo

Sponsors & Collaborators

  • Nobelpharma

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-19
Primary Completion
2020-02-04
Completion
2020-02-04

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04203862 on ClinicalTrials.gov